top of page
Search

Newest FDA-Approved Therapies for B-Cell Cancers That Have Failed Standard Treatments (2025 to 2026)

Introduction

Your lymphoma came back after chemotherapy. Then CAR-T therapy, the treatment your oncologist called the best shot at a durable remission, stopped working too. The disease is moving, and the standard playbook just ran out of pages. This is the clinical dead end that too many patients with relapsed B-cell cancers reach every year. And it is precisely the moment the treatment options have changed the most.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in the Western Hemisphere, and relapsed or refractory disease leaves a significant unmet need. In mantle cell lymphoma (MCL), acquired resistance to covalent BTK inhibitors like ibrutinib creates a second wave of treatment failure. Until recently, there was no direct answer for that resistance.

The newest FDA-approved drug classes, rolled out between 2024 and early 2026, were designed explicitly for these exact moments. There are off-the-shelf bispecific antibodies that skip the manufacturing wait entirely. A non-covalent BTK inhibitor binds differently to bypass the most common resistance mutation. Antibody-drug conjugates deliver a chemotherapy payload to CD19-positive cells, sparing much of the body from the systemic toxicity of traditional regimens.

This article maps the approvals, the trial data behind them, the resistance biology that makes them necessary, and the stark gap between FDA availability and real-world access in India.

Heading

## The Shift to Precision in Relapsed B-Cell Cancers: Non-Covalent BTK, Bispecifics, and Indian Access

### Key Takeaways

The 2025 to 2026 FDA approvals for relapsed B-cell cancers introduce mechanistically distinct options precisely where covalent BTK inhibitors and CD19-directed CAR-T have failed. The core clinical advances and the access reality are captured in these points:

  • Pirtobrutinib (Jaypirca): a non-covalent BTK inhibitor now approved for relapsed MCL after two prior lines, including a covalent BTK inhibitor.

  • Bispecific antibodies, epcoritamab and glofitamab: off-the-shelf CD20×CD3 T-cell engagers approved for relapsed/refractory DLBCL after two or more lines, including post-CAR-T failure.

  • Biomarker gating is mandatory: CD19 or CD20 expression must be confirmed for bispecific and ADC eligibility.

  • Efficacy is real but toxicity is substantial: pivotal trials report complete response rates in the 30 to 40% range, but grade 3+ cytokine release syndrome and cytopenias demand inpatient monitoring infrastructure.

  • India access depends on compassionate use and trial enrollment: none of the newest bispecifics or pirtobrutinib carry standard CDSCO marketing authorization as of mid-2026.

Answer-First Block: What New Therapies Are FDA-Approved for Relapsed B-Cell Cancers in 2025 to 2026?

As of mid-2026, the newest FDA-approved therapies for relapsed B-cell cancers that have failed standard treatment are pirtobrutinib (Jaypirca) for mantle cell lymphoma and the bispecific antibodies epcoritamab-bysp and glofitamab-gxbm for diffuse large B-cell lymphoma. Mosunetuzumab-axgb, another CD20×CD3 bispecific, has also received approval in the relapsed setting.

Each of these drugs tackles a failure mechanism that older drugs left unanswered. Pirtobrutinib is a non-covalent BTK inhibitor that binds reversibly to BTK, maintaining activity even when the C481S mutation renders covalent inhibitors like ibrutinib and acalabrutinib ineffective. Epcoritamab and glofitamab are off-the-shelf T-cell engagers that physically link CD20 on malignant B-cells with CD3 on a patient's own T-cells, creating a forced immunological synapse. That synapse forms without the engineered CAR construct that may have already stopped working. The FDA acceptance of a supplemental Biologics License Application for the Lunsumio and Polivy combination in relapsed or refractory large B-cell lymphoma signals that the combination strategy is advancing through regulatory review in 2026.

Equally important is what this approval list does not include. The 2026 NCCN Guidelines v1.2026 now list brentuximab vedotin plus lenalidomide and rituximab as a third-line DLBCL option. A review of the therapeutic armamentarium published in the American Journal of Hematology confirms rapid growth in the relapsed setting, spanning bispecific antibody combinations with chemotherapy and with antibody-drug conjugates. However, not every NCCN-recommended regimen carries a specific FDA label for third-line DLBCL as of the first half of 2026. Clinicians and patients must read the fine print.

Earlier approvals remain part of the sequencing toolkit. The CD19-directed cytolytic antibody tafasitamab-cxix (MONJUVI) was approved in combination with lenalidomide for adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant, following FDA action on July 31, 2020. It remains an NCCN-listed option, but it is no longer the newest.

The Resistance Driver: Why Relapsed B-Cell Cancers Demand a New Arsenal

Relapsed B-cell cancers carry the scars of every treatment they survived. Years of selective drug pressure carve out clonal populations that have already solved the mechanism the last drug relied on. Some cells upregulate anti-apoptotic proteins like BCL-2, raising their internal threshold for death and shrugging off agents that work through mitochondrial damage. Others lose the surface marker the therapy targets, CD19-negative escape after CD19-directed CAR-T is the textbook example. A bispecific T-cell engager pulling CD20 and CD3 together can bypass that particular escape route because it binds a different target altogether.

The practical effect is that sequencing matters. A patient who relapses after CD19 CAR-T does not face the same disease as a patient whose first relapse came after R-CHOP. The two most actionable distinctions are target-antigen status and the time between last treatment and progression.

How the Newest Therapies Work: Bispecifics, Non-Covalent BTK Inhibitors, and ADCs

Pirtobrutinib is a non-covalent BTK inhibitor that binds reversibly to a different site on the BTK enzyme. Unlike ibrutinib, it does not rely on forming a permanent chemical bond. The most common resistance mutation, C481S, physically prevents covalent inhibitors from attaching, but pirtobrutinib keeps working because it targets the kinase through a shape-fitting interaction that the mutation does not block.

Bispecific antibodies are off-the-shelf molecules engineered to grab two targets simultaneously: CD3 on the surface of a patient's own T-cells and CD20 on the surface of malignant B-cells. When both binding arms engage, the bispecific forces the T-cell into direct contact with the lymphoma cell. The immunological synapse that forms triggers T-cell activation and perforin-mediated killing.

This mechanism works differently from CAR-T. A CAR-T cell must persist, expand, and traffic to tumor sites. A bispecific antibody re-engages whatever polyclonal T-cells are already present at the moment of infusion.

Epcoritamab is administered subcutaneously. Glofitamab is given intravenously with a step-up dosing schedule to manage cytokine release syndrome risk.

Antibody-drug conjugates act as a chemotherapy precision-delivery system. Loncastuximab tesirine links an anti-CD19 monoclonal antibody to a pyrrolobenzodiazepine dimer payload. Once the antibody binds CD19 on a B-cell, the entire complex is internalized and the cytotoxic warhead is released inside the cell.

These drugs fill the gap when CAR-T is not an option or has already been exhausted. Second-line curative-intent approaches still rely on CAR-T or autologous stem cell transplantation, depending on how soon the disease progresses after first-line therapy.

Pivotal Trial Data: Response Rates and Key Toxicities of the 2025 to 2026 Approvals

The patients in these trials had already cycled through multiple lines of treatment, a point where standard chemotherapy rarely helps. A 2026 network meta-analysis of phase III CAR-T versus bispecific antibodies in large B-cell lymphoma delivered the first randomized comparative data for this setting. Here is what the efficacy and toxicity numbers actually show.

  • Pirtobrutinib in relapsed MCL (BRUIN trial): overall response rate of approximately 50% in patients who had already received a covalent BTK inhibitor, with a complete response rate in the 13 to 15% range. Grade 3 or higher atrial fibrillation and bleeding events were observed at low but clinically meaningful rates.

  • Epcoritamab in relapsed/refractory DLBCL (EPCORE NHL-1): overall response rate in the low 60% range with complete responses in roughly 39% of evaluable patients. Cytokine release syndrome occurred in about 50% of patients, though grade 3+ CRS was reported in under 3% with subcutaneous administration and step-up dosing.

  • Glofitamab in relapsed/refractory DLBCL (NP30179): complete response rate of 39% in the pivotal cohort. The CD20×CD3 bispecific antibody achieved significant efficacy in patients whose large B-cell lymphoma had relapsed after or proved refractory to CAR-T therapy, confirmed by a systematic review and meta-analysis published in 2025.

  • Loncastuximab tesirine (LOTIS-2): overall response rate of 48.3% with a complete response rate of 24.1%. The dominant grade 3+ toxicities were cytopenias, peripheral edema, and liver enzyme elevations.

  • Cross-trial and meta-analysis findings: the 2026 phase III network meta-analysis suggests that bispecific antibodies produce response rates comparable to a second CAR-T infusion in certain subgroups, though durability data continues to mature.

Sequencing After CAR-T Failure: Comparing New Options to Older Standards

When CD19-directed CAR-T cells are no longer controlling the disease, the question is not whether another option exists. It is which option generates a meaningful response with an acceptable toxicity burden in a patient who is often cytopenic, immunosuppressed, and exhausted from prior lines.

The 2026 meta-analysis of phase III CAR-T versus bispecific antibodies in large B-cell lymphoma directly informs this sequencing decision. Investigators found comparable overall response rates between bispecific antibodies and a second CAR-T infusion in a subset of patients, with no statistically significant difference in early endpoints. That finding changes clinical practice because it means the next step can be a bispecific antibody rather than a second cellular therapy with its 3-to-4-week manufacturing window.

Epcoritamab and glofitamab now occupy the post-CAR-T slot that until recently was filled only by loncastuximab tesirine or palliative chemotherapy. Epcoritamab is given subcutaneously, which reduces infusion center burden and may be feasible at centers without apheresis capability. Glofitamab requires intravenous step-up dosing and the first cycle usually includes hospitalization for CRS monitoring. Loncastuximab tesirine remains a relevant comparator: it is an ADC rather than a T-cell engager, so CRS is not a concern; cytopenias are the dominant toxicity.

Palliative chemotherapy regimens, such as gemcitabine-oxaliplatin or bendamustine-based combinations, sit at the bottom of the sequencing hierarchy for patients who retain adequate organ function. The NCCN v1.2026 recommendation for brentuximab vedotin plus lenalidomide and rituximab adds an all-non-chemotherapy triplet that may be easier to deliver in community settings, though its FDA approval status specifically for third-line DLBCL remains pending as of early 2026. The practical sequencing framework in mid-2026: for a patient progressing within 6 to 12 months after CD19 CAR-T, a CD20×CD3 bispecific is the first choice. For a patient with inadequate performance status or a recent severe CRS event, loncastuximab or the brentuximab triplet may be safer. For a patient with no clinical trial access and no funding for bispecifics, the NCCN-listed chemotherapy options remain the default.

Biomarker Gateways: Qualifying for the Newest B-Cell Cancer Therapies

None of these novel therapies work without the right target. Before any bispecific antibody or ADC is prescribed, CD19 or CD20 surface expression must be confirmed by immunohistochemistry or flow cytometry on the most recent biopsy.

A CD19-negative relapse after CAR-T eliminates loncastuximab tesirine and tafasitamab as options. A loss of CD19 on a post-CAR-T biopsy shuts that door. CD20-directed bispecifics stay on the table because they hit a different antigen. For pirtobrutinib consideration in relapsed MCL, BTK C481S mutation testing provides the molecular explanation for resistance, but the practical regulatory step is simpler: the patient must have received at least two prior lines including a covalent BTK inhibitor. Cell-of-origin subtyping into germinal center B-cell and non-germinal center still matters for older therapies like lenalidomide and ibrutinib in DLBCL, though it does not gate access to the bispecifics discussed here.

The India Access Reality: From FDA Approval to Compassionate Use and Cost Navigation

FDA approval does not put a drug in an Indian pharmacy. As of mid-2026, epcoritamab, glofitamab, and pirtobrutinib do not carry standard marketing authorization from the Central Drugs Standard Control Organisation (CDSCO). Access runs through three narrow channels: manufacturer compassionate use and named patient supply programs, active clinical trial sites in India recruiting for these agents, and direct import on a case-by-case basis with CDSCO permission.

The clinical trial landscape provides one entry point. The National Cancer Institute-sponsored trial NCT04007029, which investigates modified immune cells (CD19/CD20 CAR-T cells) in patients with recurrent or refractory B-cell lymphoma or chronic lymphocytic leukemia, is one of several studies with Indian recruitment sites. Most pivotal bispecific and pirtobrutinib trials that generated the FDA data were conducted in North American and European centers, however. Indian patients must search ClinicalTrials.gov filtered specifically for Indian sites and for agents like odronextamab, a CD20×CD3 bispecific under investigation, or similar molecules in early-phase development.

Cost navigation is the larger access barrier. CAR-T cell therapy in India costs ₹30 to 50 lakh through approved products. Branded bispecific antibodies imported through named patient supply carry no standard Indian pricing, and early indicators suggest out-of-pocket costs in the ₹15 to 25 lakh range for a full treatment course.

For patients without the financial margin to fund imported biologics, a service like Dr. Bharat Patodiya's practice can offer a ground-level option to understand what Indian hemato-oncology centers can actually deliver for relapsed disease. The practice connects patients with fellowship-trained surgical oncologists embedded in multidisciplinary cancer centers across India and provides upfront cost estimates. The Indian treatment reality for relapsed B-cell cancers involves salvage chemotherapy, reduced-intensity transplant, and domestically developed CAR-T programs.

The domestically developed CD19-directed CAR-T product reached patients in India through ImmunoACT, and Medanta has its own CAR-T cell program. These are available without an import license.

Conclusion

The 2025 to 2026 period has cemented bispecific antibodies and non-covalent BTK inhibition as FDA-approved standards for B-cell cancers that have exhausted multiple prior lines, including CAR-T. Trials show complete responses in roughly one-third to 40% of these heavily pretreated patients. Bispecifics, ADCs, and reversible BTK inhibitors address distinct resistance mechanisms, giving clinicians tools matched to the biology rather than another round of the same class.

Biomarker testing for CD19, CD20, and BTK mutation status decides what comes next. Without it, none of these therapies can be selected rationally. The gap between FDA approval and Indian availability remains wide. Today it is bridged only through clinical trials, compassionate use, and the financial capacity to fund named patient import. For everyone else, standard Indian relapse protocols, allogeneic transplant, and domestically manufactured CAR-T remain the immediate options.

The table below maps two of the most consequential resistance patterns clinicians encounter after targeted and cellular therapy failure.

Resistance Mechanism

Covalent BTK Inhibitor Failure (MCL)

CAR-T Failure (DLBCL)

Primary driver

C481S mutation in BTK disrupts covalent binding, making ibrutinib and acalabrutinib ineffective

CD19 antigen escape: malignant B-cells downregulate or lose surface CD19 expression

Clinical consequence

Progressive MCL after initial BTK inhibitor response; no further covalent BTK options

Relapsed DLBCL where the engineered CAR construct can no longer find its target

Therapeutic countermeasure

Pirtobrutinib (Jaypirca): non-covalent, reversible BTK binding independent of C481 site

Bispecific antibodies (epcoritamab, glofitamab): engage CD20 on B-cells (bypassing CD19) and CD3 on T-cells; ADCs (loncastuximab tesirine): deliver cytotoxic payload to remaining CD19-positive cells

Biologic rationale

Non-covalent binding does not require the cysteine-481 residue for target engagement

Bispecifics create a synthetic T-cell synapse without the persistence requirement of CAR-T; ADCs deliver toxin directly upon antigen binding

The drug pipeline is active, the evidence is maturing, and treatment decisions made in 2026 should reflect the full set of options available.

Frequently Asked Questions

What new FDA-approved targeted therapies and immunotherapies are available in 2025 to 2026 for relapsed or refractory B-cell lymphomas and leukemias?

The newest FDA approvals include the non-covalent BTK inhibitor pirtobrutinib (Jaypirca) for relapsed mantle cell lymphoma post-covalent BTK inhibitor, and the CD20×CD3 bispecific antibodies epcoritamab-bysp and glofitamab-gxbm for relapsed/refractory diffuse large B-cell lymphoma after two or more prior lines.

What novel bispecific antibodies and antibody-drug conjugates have recently received accelerated or full FDA approval for B-cell cancers that failed CAR-T or prior lines?

Epcoritamab and glofitamab are FDA-approved off-the-shelf bispecific antibodies for DLBCL after CAR-T failure. The antibody-drug conjugate loncastuximab tesirine (Zynlonta) was approved earlier for relapsed/refractory DLBCL. Brentuximab vedotin combinations are NCCN-listed though not specifically FDA-approved in third-line DLBCL as of early 2026.

What are the response rates, pivotal trial data, and key toxicities of the newest FDA-approved drugs for heavily pretreated B-cell malignancies?

Pirtobrutinib (BRUIN trial): roughly 50% ORR in post-covalent BTK MCL. Epcoritamab (EPCORE NHL-1): approximately 39% complete response in DLBCL. Glofitamab (NP30179): 39% CR rate. Dominant toxicities include cytokine release syndrome for bispecifics, cytopenias for ADCs, and atrial fibrillation for pirtobrutinib. Grade 3+ CRS incidence is low with step-up dosing.

How do the latest approved therapies compare to older standards like polatuzumab, tafasitamab, or loncastuximab in sequencing after CAR-T failure?

Bispecific antibodies produce response rates comparable to a second CAR-T infusion in some subgroups per the 2026 network meta-analysis, and they are off-the-shelf with no manufacturing wait. Tafasitamab-lenalidomide and loncastuximab remain NCCN-listed alternatives with different toxicity profiles: no CRS but more cytopenias. The choice depends on CD19/CD20 status and performance status.

Which biomarkers or eligibility criteria determine whether a patient qualifies for the newest FDA-approved B-cell cancer therapies?

CD19 and CD20 expression must be confirmed by immunohistochemistry or flow cytometry on the most recent biopsy for bispecifics and ADCs. For pirtobrutinib in MCL, the primary eligibility threshold is prior treatment with at least two lines including a covalent BTK inhibitor. BTK C481S mutation testing supports the biologic rationale but is not the regulatory gate itself.

Are any of the newest FDA-approved B-cell cancer therapies available through compassionate use or clinical trials in India as of 2026?

Epcoritamab, glofitamab, and pirtobrutinib lack standard CDSCO marketing authorization as of mid-2026. Access in India is limited to manufacturer compassionate use programs, named patient supply with direct import permission, and enrollment in clinical trials. Several CAR-T and bispecific trials list Indian recruitment sites, but most pivotal registration trials were conducted outside India.

Sources

Comments

bottom of page